APOTEKERNES A.M.B.A

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  3.4% 3.0% 2.5% 4.6% 1.7%  
Credit score (0-100)  56 57 60 45 71  
Credit rating  BBB BBB BBB BBB A  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 15.3  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 0.0 14,649 25,169  
EBITDA  -83.0 -117 104 57.4 5,214  
EBIT  -83.0 -117 104 13.8 4,976  
Pre-tax profit (PTP)  -106.0 6.0 90.0 9.8 4,996.6  
Net earnings  -106.0 6.0 90.0 4.6 3,203.2  
Pre-tax profit without non-rec. items  -83.0 -117 104 9.8 4,997  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 59.9 30.6  
Shareholders equity total  2,608 2,610 2,693 2,693 5,892  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  50,741 55,306 48,415 43,553 44,408  

Net Debt  0.0 0.0 0.0 -5,083 -14,639  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 0.0 14,649 25,169  
Gross profit growth  -100.0% 0.0% 0.0% 0.0% 71.8%  
Employees  0 0 0 21 22  
Employee growth %  -100.0% 0.0% 0.0% 0.0% 4.8%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  50,741 55,306 48,415 43,553 44,408  
Balance sheet change%  13.9% 9.0% -12.5% -10.0% 2.0%  
Added value  -83.0 -117.0 104.0 13.8 5,214.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -349 0 0 16 1,018  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 -2.0 1.0 2.0 3.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 0.0% 0.1% 19.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -0.2% -0.2% 0.2% 0.4% 12.0%  
ROI %  -0.3% -0.2% 0.2% 0.8% 122.7%  
ROE %  -4.0% 0.2% 3.4% 0.2% 74.6%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  100.0% 100.0% 100.0% 6.2% 13.3%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% -8,859.9% -280.7%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 0.0 0.6 0.7  
Current Ratio  0.0 0.0 0.0 1.1 1.1  
Cash and cash equivalent  0.0 0.0 0.0 5,083.1 14,639.5  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 0.0 3,339.2 5,316.3  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 1 237  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 3 237  
EBIT / employee  0 0 0 1 226  
Net earnings / employee  0 0 0 0 146